331 related articles for article (PubMed ID: 21044436)
1. Long-term safety of methotrexate in the treatment of rheumatoid arthritis.
Yazici Y
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S65-7. PubMed ID: 21044436
[TBL] [Abstract][Full Text] [Related]
2. Parenteral methotrexate for the treatment of rheumatoid arthritis.
Yazici Y; Bata Y
Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():46-8. PubMed ID: 24219041
[TBL] [Abstract][Full Text] [Related]
3. Perioperative use of methotrexate.
Heldmann F; Braun J
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S110-3. PubMed ID: 21044442
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
Castrejón I; Gibson KA; Pincus T
Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S20-8. PubMed ID: 24219037
[TBL] [Abstract][Full Text] [Related]
6. Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a short-term study.
Dhaon P; Das SK; Srivastava R; Agarwal G; Asthana A
Int J Rheum Dis; 2018 May; 21(5):1010-1017. PubMed ID: 27455886
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate: a gold standard for treatment of rheumatoid arthritis.
Shinde CG; Venkatesh MP; Kumar TM; Shivakumar HG
J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):351-8. PubMed ID: 25322199
[TBL] [Abstract][Full Text] [Related]
8. Side effects and management of side effects of methotrexate in rheumatoid arthritis.
Albrecht K; Müller-Ladner U
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S95-101. PubMed ID: 21044440
[TBL] [Abstract][Full Text] [Related]
9. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
10. [Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].
Nesa L; Gobbi C; Alba P; Exeni I; Babini A; Albiero E
Rev Fac Cien Med Univ Nac Cordoba; 2007; 64(4):109-14. PubMed ID: 19928400
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study.
Luis M; Pacheco-Tena C; Cazarín-Barrientos J; Lino-Pérez L; Goycochea MV; Vazquez-Mellado J; Burgos-Vargas R
Arthritis Rheum; 1999 Oct; 42(10):2160-5. PubMed ID: 10524688
[TBL] [Abstract][Full Text] [Related]
13. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
[TBL] [Abstract][Full Text] [Related]
14. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
[TBL] [Abstract][Full Text] [Related]
15. Optimal administration and dosage of methotrexate.
Braun J
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S46-51. PubMed ID: 21044433
[TBL] [Abstract][Full Text] [Related]
16. Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients.
Pincus T; Furer V; Sokka T
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S68-79. PubMed ID: 21044437
[TBL] [Abstract][Full Text] [Related]
17. [MTX].
Kaneko Y
Nihon Rinsho; 2016 Jun; 74(6):944-7. PubMed ID: 27311183
[TBL] [Abstract][Full Text] [Related]
18. [Methotrexate: mainstay of rheumatoid arthritis treatment].
Jacobs JW; Bijlsma JW
Ned Tijdschr Geneeskd; 2009; 153():A879. PubMed ID: 19785862
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis.
Dhir V; Singla M; Gupta N; Goyal P; Sagar V; Sharma A; Khanna S; Singh S
Clin Ther; 2014 Jul; 36(7):1005-15. PubMed ID: 24976447
[TBL] [Abstract][Full Text] [Related]
20. Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies.
Jacobs JW
Rheumatology (Oxford); 2012 Jun; 51 Suppl 4():iv27-33. PubMed ID: 22685273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
